Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018
In January 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) announced a five-year agreement that will reduce drug prices for all Canadians who use prescription generic drugs, participating public drug plans, and employee drug plans.
The prices of nearly 70 of the most commonly prescribed generic drugs in Canada will be reduced by 25% – 40% effective April 1st, 2018, representing discounts of up to 90% off the corresponding innovative brand prices.
For more information please see pCPA’s Pan-Canadian Generic Value Price Initiative Generic Pricing Framework available here. The complete list of Pan-Canadian molecules with new price points effective April 1, 2018 can be found here.
Reminder: Application fees for CADTH Pharmaceutical Reviews become effective April 2nd, 2018
In February 2018, CADTH announced that application fees will be adjusted for the review of a drug submission or resubmission filed with CADTH Common Drug Review (CDR) and the CADTH pan-Canadian Oncology Drug Review (pCODR).
Application fees will be adjusted annually based on fluctuations in the Consumer Price Index and applies for all submissions or resubmissions received on or after April 2nd, 2018.
Please review the updated Guidelines for Manufacturers on Application Fees for CADTH Pharmaceutical Reviews for the adjusted fee schedule (Table 1: Application Fee Schedule). Application fees will not apply to any submission, resubmission, or request for advice filed by the CADTH Pharmaceutical Review-participating drug plans and tumour groups.
Please see CDR Update 135 for additional information.